Indivior PLC
ISIN GB00BN4HT335
|WKN A3DWFC
Overview
Description
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,098.90 m |
| EPS, EUR | -0.24 |
| P/B ratio | 142.15 |
| P/E ratio | 625.33 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 1,098.28 m |
| Net income, EUR | 1.85 m |
| Profit margin | 0.17% |
What ETF is Indivior PLC in?
There are 26 ETFs which contain Indivior PLC. All of these ETFs are listed in the table below. The ETF with the largest weighting of Indivior PLC is the Deka STOXX Europe Strong Value 20 UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
